paper_id,claim,figure_id,title,caption,local_image_path,url
PMC6261116,"Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing > 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. 1).",PMC6261116_figure_1,Fig. 1.,"Study design of the CLARITY study. ¥Ustekinumab dose is based on body weight at baseline; 45 mg for patient ≤ 100 kg; 90 mg for patient > 100 kg. †For patients with premature treatment discontinuation only. F4 = follow-up visit approximately 4 weeks after the EOT visit. F8 = follow-up visit approximately 8 weeks after the EOT visit. ↓ = active dose administration; in order to maintain blinding, patients received placebo administrations at several time points (not shown in this study design figure). The screening phase duration was at least 2 weeks and up to 4 weeks. BL baseline, EOT end of treatment phase",./data/PMC6261116/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b188/6261116/d7fd9ad27edd/13555_2018_265_Fig1_HTML.jpg
PMC6261116,The rate of discontinuation was low and balanced between treatment arms (Fig. 2).,PMC6261116_figure_2,Fig. 2.,Patient disposition,./data/PMC6261116/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b188/6261116/3c729646eae5/13555_2018_265_Fig2_HTML.jpg
